Physician

Elizabeth Herrington, D.O.

According to 2025 Medicare claims, Elizabeth Herrington, D.O. (NPI: 1306043278) practices internal medicine in the Jackson, MS market, with the plurality of this provider's patient population coming from Madison, MS. This provider's primary affiliated billing organization is JACKSON ONCOLOGY ASSOCIATES (NPI: 1295776136; TIN: 640619700) and primary practice location at 39216-4121. Herrington is affiliated with the CHSPSC ACO 14, LLC (ACO ID: A3724) and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Herrington's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,133 traditional Medicare patients, billed 222,086 HCPCS/CPT codes, and received $4,129,811 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,621 prescription claims across 408 beneficiaries totaling $8,396,908 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 141 claims. Open Payments data shows 75 records totaling $1,474. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $14,446 to $4,129,811. Similarly, Part D prescription costs have moved sharply higher in recent years, from $4,723 to $8,396,908. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $2,552 to $3,758.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	87	256	$14,446
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	30	48	$3,150
2019	433	182,434	$1,842,552
2020	476	203,361	$2,747,500
2021	459	228,161	$3,020,637
2022	577	207,270	$3,244,477
2023	956	252,019	$3,867,740
2024	1,133	222,086	$4,129,811

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	46	119	$4,723
2016	N/R	36	$328
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	162	1,035	$2,573,994
2020	188	1,480	$4,073,847
2021	197	1,439	$3,534,319
2022	231	1,589	$4,118,321
2023	369	1,968	$5,576,129
2024	408	2,621	$8,396,908

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	13	$3,143
2020	N/R	22	$1,412
2021	N/R	43	$2,748
2022	N/R	N/R	N/R
2023	N/R	84	$14,160
2024	23	141	$3,812

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	502	1,041	$88
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	488	667	$62
80053	Blood test, comprehensive group of blood chemicals	774	1,981	$10
36415	Insertion of needle into vein for collection of blood sample	753	2,299	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	815	2,789	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	104	2,884	$1,166,994
Imbruvica	Ibrutinib	79	2,212	$1,152,337
Jakafi	Ruxolitinib Phosphate	57	1,770	$1,066,406
Revlimid	Lenalidomide	59	1,624	$965,131
Cabometyx	Cabozantinib S-Malate	29	870	$713,205

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	11	41	$1,439
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	12	39	$678
J8700	Temozolomide, oral, 5 mg	N	N/R	11	$611
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	27	$401
K0003	Lightweight wheelchair	Y	N/R	12	$352

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	75	$1,474	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Elizabeth Herrington, D.O.?

Tedicare shows public-source Medicare data for Elizabeth Herrington, D.O. (NPI 1306043278), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Elizabeth Herrington, D.O. have ACO affiliation data?

Elizabeth Herrington, D.O. is shown with ACO affiliation data for CHSPSC ACO 14, LLC (MSSP, ACO ID A3724) and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Elizabeth Herrington, D.O.?

Elizabeth Herrington, D.O. is linked to JACKSON ONCOLOGY ASSOCIATES (billing NPI 1295776136) in the available physician profile data.

Does Elizabeth Herrington, D.O. have Open Payments data?

Elizabeth Herrington, D.O. has 75 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.